FDA Approves Ibtrozi for ROS1-Positive NSCLC

The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Efficacy was evaluated in patients with locally advanced or metastatic, ROS1-positive NSCLC enrolled in two multicenter, single-arm, open-label clinical trials: TRUST-I (ClinicalTrials.gov Identifier: NCT04395677) and TRUST-II (NCT04919811). The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who